Chronic lymphocytic leukemia: A disease of dysregulated programmed cell death
- 30 September 1997
- journal article
- Published by Elsevier in Clinical Immunology Newsletter
- Vol. 17 (9), 125-130
- https://doi.org/10.1016/s0197-1859(00)80016-3
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Tumour suppressors: A developing role for p53?Current Biology, 1997
- Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosisLeukemia, 1997
- In leukaemic CD5+ B cells the expression of BCL‐2 gene family is shifted toward protection from apoptosisBritish Journal of Haematology, 1996
- The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein.Genes & Development, 1996
- A unique spectrum of p53 mutations in B‐cell chronic lymphocytic leukemia distinct from that of other lymphoid malignanciesMolecular Carcinogenesis, 1995
- Interaction of viral and cellular proteins with the retinoblastoma tumour suppressor gene productReviews in Medical Virology, 1995
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- Germinal center cells express bcl‐2 protein after activation by signals which prevent their entry into apoptosisEuropean Journal of Immunology, 1991
- Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia.The Journal of Experimental Medicine, 1990
- Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocationCell, 1986